What indicators need to be monitored while taking Selinexor?

Selinisol is a selective nuclear export inhibitor used primarily to treat patients with multiple myeloma and certain lymphomas. Due to its special mechanism of action and potential side effects, multiple indicators need to be closely monitored while taking selinesol to ensure patient safety and therapeutic effect. First of all, hematological indicators are the key monitoring content. Selinisol may cause bone marrow suppression, leading to leukopenia, thrombocytopenia and anemia. Therefore, routine blood tests need to be checked regularly, with special attention to neutrophil and platelet counts, to prevent and deal with the risk of infection or bleeding in a timely manner.

Secondly, monitoring liver and kidney function is also very important. The metabolism of selinesol in the body involves the liver and may have certain effects on liver function. Regular detection of liver function indicators such as ALT, AST and total bilirubin can help detect liver damage early and avoid serious liver function abnormalities. At the same time, renal function indicators such as serum creatinine and urea nitrogen should also be checked regularly to evaluate the kidney status, especially patients with renal insufficiency.

Third, the monitoring of electrolytes and metabolic indicators cannot be ignored. Electrolyte disorders such as hyponatremia and hypokalemia may occur during selinesol treatment, affecting cardiac and nervous system functions. Regular testing of blood sodium, blood potassium, blood calcium and other ion levels can help correct abnormalities in time and avoid serious complications. At the same time, the patient's weight, nutritional status, and water and electrolyte balance also need to be paid attention to.

Finally, the patient's clinical symptoms and living status should also be closely observed. Common side effects of selinesol include nausea, fatigue, loss of appetite, etc. Timely reporting of these symptoms can help doctors adjust the dosage of the drug or take supportive treatment measures. Combining various monitoring indicators can maximize patient safety and improve the effectiveness and tolerability of treatment.

Reference materials:https://www.selincro.com/